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E-mail address: rperera@sanfordburnham.org (R.J.To identify epigenetically regulated miRNAs in melanoma, we treated a stage 3 melanoma cell line
WM1552C, with 5AzadC and/or 4-PBA. Several hypermethylated miRNAs were detected, one of
which, miR-375, was highly methylated and was studied further. Minimal CpG island methylation
was observed in melanocytes, keratinocytes, normal skin, and nevus but hypermethylation was
observed in patient tissue samples from primary, regional, distant, and nodular metastatic mela-
noma. Ectopic expression of miR-375 inhibited melanoma cell proliferation, invasion, and cell
motility, and induced cell shape changes, strongly suggesting that miR-375 may have an important
function in the development and progression of human melanomas.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Melanoma is the most lethal form of skin cancer in the United
States and the risk of developing melanoma is increasing [1]. A
number of protein-coding genes [2] have been identiﬁed as poten-
tial biomarkers and candidate drug targets for melanoma [3–9].
Several of these genes exhibit distinct expression signatures
among a variety of malignant metastatic melanomas and their be-
nign forms [2]. Recently, a group of small non-coding RNA mole-
cules, especially microRNAs (miRNAs) have garnered increasing
attention for their potential roles in tumorigenesis [10–14], includ-
ing in melanoma [15–19]. miRNAs are thought to inﬂuence cancer
development by regulating transcription and translation of tumor
suppressor genes and oncogenes [20–26]. Several genome-wide
expression studies, including our own study of Mazar et al. [27],
have implicated a number of miRNAs that could be important
players for melanoma development [9,19,28–30]. For example,
miR-221/222 was found to down-regulate 27Kip1/CDKN1B and
the c-KIT receptor, which controls the neoplastic transformation
that leads to enhanced proliferation and reduced differentiation
in melanoma cells [28]. Similarly, miR-137 down-regulates
microphthalmia associated transcription factor (MITF) expression
in melanoma cell lines. Thus, there is precedent for miRNA as reg-
ulators of melanocyte cell growth, maturation, apoptosis, and pig-chemical Societies. Published by E
Perera).mentation [19]. In a recent study, the mechanistic role of miR-211
on melanoma development was reported [27,30].
Our results with melanoma cell lines and clinical samples indi-
cate that several miRNA species are epigenetically regulated in
melanomas and we report here for the ﬁrst time the molecular
mechanisms by which one such miRNA, miR-375, might affect
melanoma development in humans. Though miR-375 has been
previously reported as important miRNA in the pancreas and brain
[31–33], its function is not known in melanoma. We believe that
the ﬁnding that miRNA-375 is epigenetically modiﬁed contributes
signiﬁcantly to our understanding of the events regulating mela-
noma development, and will eventually lead to the development
of novel diagnostic and therapeutic tools.
2. Materials and methods
2.1. Cell lines and clinical samples
The experimental studies in this manuscript utilized the human
epidermal melanocyte cell line HEM-l (ScienceCell, Catalog #2200,
grown in MelMmedia containing MelGS growth supplements, 0.5%
FBS, and penn/strep solution), human epidermal keratinocytes
(HEK, ScienCell, Catalog #2100, grown in Keratinocyte Medium,
ScienCell, Catalog #2101), and the melanoma cell lines WM793B
(stage 1, Wistar Institute), WM278 (stage 2, Wistar Institute),
WM1552C (stage 3, ATCC Number: CRL-2808), and A375 (stage
4, American Type Culture Collection). All melanoma cell lines werelsevier B.V. All rights reserved.
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153 medium with 1.5 g/l sodium bicarbonate and Leibovitz’s L-
15 medium with 2 mM L-glutamine, 2% FBS, and 1.68 mM CaCl2.
All clinical samples were graciously donated by Dr. James Goydos,
Robert Wood Johnson Medical School. Patient samples information
listed [27].
2.2. Cell labeling and imaging
Live cells were imaged under normal culture conditions by light
microscope (Olympus IX71). The morphology time course experi-Fig. 1. Activation of epigenetically modiﬁed miRNAs in response to 5AzadC and 4-PBA.
both. Expression levels were measured by two miRNA proﬁling platforms (TILDA; ABI a
expression in non-treated controls.
Fig. 2. miRNA-375 CpG island methylation in melanocytes, keratinocytes, and melanoma
genomic sequencing. 170 to +58 represent nucleotides relative to the pri-miR-375 geno
represent the positions of CpG sequences. Each cell line was tested with nine clones
WM793B = stage 1; WM278 = stage 2; WM1552C = stage 3; A375 = stage 4.ment was performed with cells growing exponentially, trypsinized
and seeded with 2  104 cells into 4 well Lab-Tek II chamber slides
(Thermo Fisher Scientiﬁc), with one slide per time point. At the
designated time points (4, 24, 48, and 72 h), the slides were
washed in PBS and ﬁxed in 4% formaldehyde in PBS. The slides
were then labeled with DAPI and ﬂuorescence-labeled phalloidin,
then imaged on a Nikon Eclipse microscope.
2.3. Genomic DNA isolation and bisulﬁte treatment
See Supplementary material.Differentially expressed miRNAs in melanoma cells treated with 5AzadC, 4-PBA, or
nd NCode; Lifetech), and are presented as fold increase or decrease compared with
cells. CpG island methylation frequency in themir-375 loci as measured by bisulﬁte
mic sequence, with the arrow representing the pri-miR-375 start site. Vertical lines
. Black boxes represent methylated sites; white boxes represent no methylation.
J. Mazar et al. / FEBS Letters 585 (2011) 2467–2476 24692.4. CpG Island methylation detection by the sequencing of bisulﬁte
converted PCR products from genomic DNA
See Supplementary material.
2.5. Treatment of WM1552C cells with 5-aza-20-deoxycytidine (5-Aza-
dC) or 4-phenylbutyric acid (PBA)
See Supplementary material.
2.6. Northern blot analysis
See Supplementary material.
2.7. DNA pyrosequencing
See Supplementary material.
2.8. Construction of stably-expressing miR-375 melanoma cell line
See Supplementary material.
2.9. Next generation DNA sequencing/RNA-seq
See Supplementary material.
2.10. RNA-Seq data analysis
See Supplementary material.Fig. 3. miR-375 CpG island methylation in patient samples, melanocytic nevus, and no
bisulﬁte genomic sequencing (annotation conventions are as in Fig. 2). Each patient s
(R) = regional metastasis melanoma; (D) = distant metastasis melanoma; (N) = nodal me2.11. Cell proliferation assay
See Supplementary material.
2.12. In vitro wound healing assay
See Supplementary material.
2.13. Invasion assays
See Supplementary material.
3. Results
3.1. Identiﬁcation of epigenetically modiﬁed miRNA-375 in melanoma
cells
To identify transcriptional changes in melanoma cells induced
by DNA methylation and/or histone modiﬁcation, we treated the
stage 3 melanoma cell line WM1552C with the DNA methyltrans-
ferase inhibitor 5-aza-2-deoxycytidine (5AzadC), the histone
deacetylase inhibitor 4-phenylbutyrate (4-PBA), or with both. Fol-
lowing exposure, cellular miRNA expression was compared be-
tween treated and untreated cells using two miRNA expression
proﬁling platforms (TILDA; ABI and NCode; Lifetech). Both plat-
forms identiﬁed the same miRNAs as being up-regulated in
WM1552C cells after treatment with 5AzadC and/or 4-PBA. Fig. 1
shows that miRNAs are highly modulated by treatment with
5AzadC and PBA. Several of the up-regulated miRNAs containrmal skin. CpG island methylation frequency in the mir-375 loci as measured by
ample was tested with six clones. Patient samples are: (P) = primary melanoma;
tastasis melanoma.
Table 1
Pyrosequencing of upstream CpG islands of miR-375 in patient samples, normal skin, nevus, and melanoma cell lines. Pyrosequencing measurements are given as an average of methylation of a given site, using normal skin, nevus,
WM278 (stage 1) and A375 (stage 4) melanoma cell lines. The positive methylation cut-off was set at 20%. Patient samples are grouped as primary, regional metastases, d ant metastases, and nodal metastases melanoma.
Sample
#
miR-375% methylation Avg%
methylation
Primer FS2 Primer FS3 Primer FS4
CpG
Site 1
CpG
Site 2
CpG
Site 3
CpG
Site 4
CpG
Site 5
CpG
Site 6
CpG
Site 7
CpG
Site 8
CpG
Site 9
CpG
Site
10
CpG
Site
11
CpG
Site
12
CpG
Site
13
CpG
Site
14
CpG
Site
15
CpG
Site
16
CpG
Site
17
CpG
Site
18
CpG
Site
19
CpG
Site
20
CpG
Site
21
Normal
skin
3 2 2 3 2 2 2 3 3 4 3 3 2 3 2 2/2 3/2 4/3 4/4 2/2 2/1 2.60 Normal
skin
Nevus 5 2 2 3 4 2 3 3 2 8 5 9 2 4 4 3/5 3/1 3/3 3/4 3/7 3/4 3.87 Nevus
WH7938 3 3 3 3 3 3 3 3 3 3 2 3 3 4 3 3/4 4/4 3/4 2/2 3/3 2/2 3.00 WH7938
A375 78 75 90 85 85 86 92 96 96 93 86 95 75 96 74 87/96 92/96 91/93 82/82 96/98 63/77 86.80 A375
Primary melanomas
10 51 48 48 50 47 50 49 51 51 52 12 54 43 58 53 49/54 54/53 52/53 53/53 55/54 43/49 47.88 10
14 29 28 28 28 27 27 29 30 28 30 28 31 25 34 29 27/30 29/28 33/32 30/31 29/29 23/26 28.73 14
21 6 4 5 5 5 2 5 5 4 9 5 7 4 4 5 5/5 6/6 6/3 5/5 5/4 3/4 5.00 21
22 6 6 6 5 6 4 3 5 4 9 4 7 4 5 3 3/3 5/3 5/8, 5/3 5/5 3/3 5.13 22
23 12 10 8 10 11 6 8 7 6 12 9 8 5 10 7 6/10 9/9 8/11 7/9 8/9 5/7 8.60 23
24 47 42 28 91 23 45 42 45 46 43 42 46 38 50 45 43/49 47/46 48/50 44/45 48/47 33/40 44.87 24
Regional metastases
3 22 20 20 21 17 19 22 20 21 21 17 9 17 24 20 19/22 21/22 29/32 23/25 22/25 24/29 19.33 3
6 10 0 1 2 1 1 9 2 9 2 3 2 1 2 1 1/2 2/1 17/19 1/1 2/1 17/20 3.07 6
27 18 13 11 28 15 19 18 19 25 22 9 18 15 21 20 18/25 21/23 26/26 22/24 20/23 24/28 18.07 27
28 53 49 51 50 40 44 57 51 33 52 45 42 42 42 35 27/29 38/38 40/41 43/42 40/44 38/45 45.73 28
29 31 32 32 44 36 32 44 34 32 29 22 28 19 32 15 16/18 25/26 28/29 28/27 25/25 28/31 30.80 29
30 4 2 2 2 1 3 5 2 6 6 8 2 1 1 1 2/2 2/1 6/6 1/1 2/1 4/5 3.07 30
Distant metastases
9 15 6 5 7 5 5 13 5 16 7 5 2 4 5 5 4/5 5/5 12/14 5/5 6/6 23/27 7.00 9
13 35 36 45 29 32 25 56 37 36 53 35 41 31 36 29 25/20 40/35 45/51 46/46 49/71 39/8 37.07 13
17 46 45 46 45 38 43 42 45 37 40 39 44 35 50 43 40/45 44/45 44/48 44/45 46/48 40/48 42.53 17
18 8 7 7 9 7 7 9 7 9 10 6 7 7 9 7 7/9 8/7 11/13 8/9 10/11 15/18 7.73 18
25 31 30 29 33 27 31 32 29 31 30 26 15 25 34 31 29/32 32/31 47/50 33/33 31/32 31/35 28.93 25
26 36 13 20 25 23 22 34 36 23 35 33 25 23 35 28 26/30 25/22 24/24 34/35 31/32 27/29 27.40 26
Nodal metastases
1 19 16 17 18 16 14 17 17 17 19 15 17 14 19 16 12/14 17/17 19/20 18/19 17/18 14/17 16.73 1
2 36 36 36 41 35 32 34 38 34 36 33 34 29 41 27 31/35 36/39 38/39 36/37 38/39 50/56 34.80 2
4 21 21 18 20 17 19 47 19 47 21 19 21 17 21 17 12/14 21/21 21/22 22/21 21/22 18/20 23.00 4
5 34 36 35 34 35 28 31 33 28 35 32 30 27 35 28 16/17 31/33 34/35 33/32 33/34 27/31 32.07 5
7 4 3 2 5 4 1 5 3 5 4 3 2 1 2 3 2/2 3/2 5/13 7/7 5/5 5/13 3.13 7
8 11 15 13 11 9 9 11 9 11 13 11 8 9 11 8 8/9 10/10 12/12 10/10 11/11 11/12 10.60 8
Primers FS3 and FS4 overlap at CpG sites 16–21; columns show % methylation for both primers.
Those bolded appear to be 20% methylated or more.
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J. Mazar et al. / FEBS Letters 585 (2011) 2467–2476 2471CpG islands in their putative regulatory regions and some have
previously been shown by bioinformatic analysis to contain CpG is-
lands [34], suggesting that reactivation of miRNA expression in
WM1552C cells may be epigenetically controlled. miR-375 was
highly up-regulated after the treatment of WM1552C cells with
5AzadC and 4-PBA, and therefore, we focused our investigation
on miR-375.
3.2. miR-375 CpG island methylation in melanocytes, keratinocytes,
and melanoma cells
Epigenetically regulated miRNAs often carry modiﬁcations such
as cytosine methylation in CpG islands located in their upstream
regulatory regions. To determine if this was the case for
miR-375, we examined methylation patterns within the CpGFig. 4. Effect of miR-375 on melanoma cell morphology. (A) Bright-ﬁeld images of me
WM1552C/375). (B) Melanoma cells were seeded and examined by ﬂuorescence microsco
with FITC-labeled phalloidin for staining (green). Melanoma cells that ectopically expreislands located 1 Kb upstream of miRNA-375 in melanoma cells,
and as controls, in normal melanocytes and keratinocytes.
Several CpG islands were identiﬁed in the upstream region of
miR-375, one of which is located from 170 to +58 bp upstream
of miRNA-375 and contains 32 CpG dinucleotides (Fig. 2). For this
study, we analyzed CpG methylation solely within this region. To
do this, genomic DNA from the cell were bisulﬁte treated, and
the miR-375 upstream CpG island was cloned, sequenced, and
the data was compared to the untreated genomic DNA. As shown
in Fig. 2, the CpG island located 170 to +58 bp upstream of miR-
NA-375 was entirely unmethylated in keratinocytes (0.0%), and
only poorly methylated in the stage 1 melanoma cell line
WM793B (0.5%) and in melanocytes (6.2%). In contrast, extensive
methylation was detected in DNA from the stage 2 melanoma line
WM278 (53.7%), the stage 3 line WM1552C (68.2%), and the stagelanoma cell lines showing growth characteristics (WM1552C, WM1552C/VO, and
py over a period of 72 h. Cells were labeled with DAPI for nuclear staining (blue) and
ss miR-375 showed signiﬁcant changes in cell morphology.
2472 J. Mazar et al. / FEBS Letters 585 (2011) 2467–24764 line A375 (92.7%). These results show that the proportion of
methylated CpG dinucleotides in the miR-375 island increased
with advancing melanoma stage, suggesting that epigenetic
changes in this CpG island may be stage speciﬁc.
To determine if methylation of CpG islands may be responsible
for down-regulation of miR-375 expression in melanoma, we ﬁrst
conﬁrmed the effect of 5AzadC treatment on the methylation state
of the region. Genomic DNA from 5AzadC-treated WM1552C cells
was treated with bisulﬁte and sequenced. Supplementary Fig. 1A
shows that 5AzadC treatment greatly reduced methylation levels
from 68.2% to 16.7% at this location. Next, WM1552C cells were
treated with 5AzadC, 4-PBA, or both, to determine their effect on
miR-375 expression as measured by Northern blotting (Supple-
mentary Fig. 1B). The results show that miR-375 expression was
induced by 5AzadC but not by 4-PBA treatment. However, a syner-
gistic effect of 5AzadC and 4-PBA was observed, resulting in greater
induction of miR-375 than after treatment with 5AzadC alone.
These data show that demethylation of miR-375 induces its
expression, conﬁrming that miR-375 is epigenetically regulated.Fig. 5. Effect of miR-375 on melanoma cell growth, viability, and invasion. (A) Proliferat
direct microscopic cell counting. (B) Cell viability of WM1552C, WM1552C/VO, and W
1.5  104 cells/well. (C and D) Cell invasion assay of WM1552C, WM1552C/VO, and WM
indicated by an asterisk (Kruskal–Wallis non-parametric test, P < 0.005).3.3. CpG island methylation of miR-375 in normal skin and melanoma
patient tissues
To conﬁrm that our ﬁndings with melanoma cell lines are rele-
vant to human pathology, we next measured CpG island methyla-
tion for miR-375 in ex vivo tissue samples from melanoma
patients. In samples of normal skin and nevi the miR-375 CpG
island was almost entirely unmethylated (Fig. 3), consistent with
the lack of methylation seen previously in keratinocytes, the dom-
inant cell type in normal skin (Fig. 2).
Next, we examined miR-375 CpG island methylation in four
groups of tissue from 24 melanoma patients: (1) primary mela-
noma, (2) regional metastases, (3) distant metastases, and (4) no-
dal metastases (Fig. 3). The results indicate that 3 of the 6
primary melanoma tissues (P), 3 of the 6 regional metastases (R),
4 of the 6 distant metastases (D), and 3 of the 6 nodal metastases
(N) were hypermethylated, with average hypermethylation of
77.4%. CpG methylation in these samples was conﬁrmed by DNA
pyrosequencing (Table 1). In addition to patient samples, we alsoion of WM1552C (wild type), WM1552C/VO, and WM1552C/375 cells over 96 h by
M1552C/375 as measured by the MTS assay at cell densities of 5  103, 104, or
1552C/375 cells. All assays were performed in triplicate. Statistical signiﬁcance is
J. Mazar et al. / FEBS Letters 585 (2011) 2467–2476 2473pyrosequenced DNA from normal skin, nevus, and the melanoma
cell lines WM793B (stage 1) and A375 (stage 3) cell lines as con-
trols. Table 1 shows that the results correlated well with previous
bisulﬁte sequencing results, and revealed lowmethylation levels in
normal skin and nevus, with average methylation of 2.6%, and 3.9%,
respectively. As expected, high methylation levels were detected in
stage 3 A375 cells (86.8%). Of the patient samples, 12 of the 13
samples positively identiﬁed by bisulﬁte sequencing as having
hypermethylated CpG were conﬁrmed by pyrosequencing (with a
positive match cut-off set at 20%, only regional metastatic patient
sample #3 fell below, with average methylation at 19.33%). qRT-
PCR results show that miR-375 expression is low compared to nor-
mal skin or nevi (Supplementary Fig. 2). Collectively, these results
show that the methylation state of the miR-375 CpG island in-
creases consistently with the transition from normal skin to mela-
noma, and further indicates the diagnostic potential of this marker
for pathological staging of melanoma.
3.4. The effect of miR-375 ectopic expression on cellular morphology,
cell growth, migration, and invasion in melanoma cells
To investigate the physiological role of miR-375 in melanoma
cells, miR-375 was ectopically expressed in the melanoma cell line
WM1552C and assayed for phenotypic changes. Changes in cellular
morphology of stable miR-375-expressing melanoma cells were
compared with ‘‘vector-only’’ and untransfected cells (Fig. 4).
Viewed by light microscopy, the miR-375-expressing cells
exhibited a more slender and elongated shape compared to the
wild type and vector control cells, which were similar in appear-
ance (Fig. 4A). These cells were also examined by ﬂuorescence
microscopy after staining with FITC-labeled phalloidin to visualizeFig. 6. Effect of miR-375 on melanoma cell motility. (A and B) Wound healing assay o
wound healing assays for WM1552C/375 compared to WM1552C/VO cells over a 20 h pe
wounds over a 20 h period, calculated using NIS elements software. Assays were perfor
non-parametric test, P < 0.005).ﬁlamentous actin. Fig. 4B shows that the morphological changes in
miR-375-expressing cells were time-dependant, with changes
detectable within 4 h after trypsinization and reseeding, and elon-
gated ﬁlapodia-like extensions visible by 24 h. These changes ap-
peared complete by 72 h. By comparison, both untransfected
WM1552C and WM1552C/VO cells acquired their characteristic
rounded shape by 4 h, and little change in morphology was seen
thereafter (Fig. 4B). A background of phospho-cortactin staining
can be seen in some cells (red color).
We next examined the effect of miR-375 expression on the cel-
lular properties of these melanoma cells. Fig. 5A shows that prolif-
eration of WM1552C/375 cells was reduced approximately 10–15%
compared to that of WM1552C orWM1552C/VO cells, as measured
by direct cell counting, and the decrease was sustained over the
96 h assay. Cell viability was examined by the MTS assay, with
the results demonstrating that WM1552C/375 cells produced
15–20% less formazan product than either WM1552C or
WM1552C/VO cells (Fig. 5B), indicating a slight reduction in mito-
chondrial metabolism that may reﬂect reduced cell viability. Apop-
tosis was examined by caspase 3/7 assays (Supplementary Fig. 3);
however, in this assay no signiﬁcant differences were noted be-
tween miR-375 expressing cells and either wild type or vector-
expressing cells.
The invasive properties of miR-375 expressing melanoma cells
were measured in standard Boudin invasion assays. Our results
(shown in Fig. 5C and D) indicate that WM1552C/375 cells mi-
grated at less than 50% the frequency of either wild type or vec-
tor-expressing cells. The reduction in cell invasion exhibited by
miR-375-expressing cells is greater than the observed effect on cell
proliferation or viability (Fig. 5A or Fig. 5B), suggesting that these
two effects of miR-375 expression occur independently. Transfec-f melanoma cells WM1552C/VO and WM1552C/375. (A) Representative images of
riod. (B) The bar graph depicts quantitation of the percent surface area between the
med in triplicate. Statistical signiﬁcance is indicated by an asterisk (Kruskal–Wallis
2474 J. Mazar et al. / FEBS Letters 585 (2011) 2467–2476tion of an miR-375 inhibitor into theWM1552C/375 cells appeared
to partially reverse the effect on migration (to 75% of wild type),
conﬁrming that the loss of function is likely due to the up-regula-
tion of miR-375.
The in vitro motility of transfectants was measured in a wound-
healing assay, and a striking difference was noted in the rates of
motility of cells expressing miR-375 as early as 4 h after initiation
of the assay (Fig. 6A and B). By 12 h of incubation, wound healing
was nearly complete in cultures of WM1552C/VO cells, whereas
migration of WM1552C/375 cells was dramatically reduced with
less than 30% wound closure by 20 h.
3.5. The global gene expression proﬁling of stable miR-375-expressing
melanoma cell lines by next-generation sequencing reveals putative
target genes
The identiﬁcation of regulatory targets for miRNAs becomes
more signiﬁcant as their importance in normal cell function and
disease becomes apparent. To further probe the pathological rele-
vance of miR-375 on malignant melanoma, total RNA was isolated
from WM1552C cells stably expressing miR-375 or transfected
with empty vector only (WM1552C/375 or WM1552C/VO). Total
RNA was reverse transcribed into cDNA, and analyzed by next-
generation sequencing. The sequences were mapped to the human
genome and mined for differences in RNA species expression.Fig. 7. Pathway analysis of putative miR-375 target genes. Pathway mapping of the 2
ectopically expressing miR-375. Thirteen of these putative targets are associated in a n
function (Ingenuity Pathway Analysis).Twenty candidate target genes were identiﬁed as highly differen-
tially expressed (Supplementary Fig. 4). Systems level pathway
mapping (Ingenuity pathway maps) revealed that 13 of the 20 can-
didate genes mapped to a single network regulating cellular and
connective tissue development and function (Fig. 7), supporting
the notion that miR-375 regulates genes associated with cellular
morphology and tissue networking.
4. Discussion
Epigenetic modiﬁcation of DNA, such as methylation and/or his-
tone modiﬁcation, is thought to play a key role in cancer progres-
sion. In melanoma, epigenetic modiﬁcations may silence or reduce
the expression of miRNAs but their expression can be reactivated
upon treatment with DNA methyltransferase inhibitors such as
5-aza-2-deoxycytidine (5AzadC), or histone deacetylating agents
such as 4-phenylbutyrate (4-PBA). To identify miRNAs that may
be important in the development of melanoma, we treated a stage
3 melanoma cell line WM1552C, with 5AzadC and/or 4-PBA. Sev-
eral hypermethylated miRNAs were detected, one of which, miR-
375, was highly methylated and was studied further.
Recently, miR-375 hypermethylation was reported in breast
cancer and gastric cancer [35,36]. In breast cancer, higher expres-
sion of miR-375 in ERa-positive breast cell lines was shown to
inﬂuence cell proliferation, and miR-375 overexpression caused0 most down-regulated miR-375 target genes (TargetScan 5.1) in melanoma cells
etwork involving the regulation of cellular and connective tissue development and
J. Mazar et al. / FEBS Letters 585 (2011) 2467–2476 2475loss of epigenetic marks including H3K9me2 and local DNA
hypomethylation. Inhibition of miR-375 in ERa-positive MCF-7
cells reduced both ERa activation and cell proliferation [35]. In gas-
tric cancer, miRNA-375 was found to be the most down-regulated
miRNA, and ectopic expression of miRNA-375 in gastric carcinoma
cells markedly reduced cell viability by a mechanism involving the
caspase-mediated apoptosis pathway [37]. Interestingly, the
authors reported that expression of miR-375 inhibited expression
of PDK1, a direct target of miR-375, and resulted in the suppression
of Akt phosphorylation [36].
Our present results show for the ﬁrst time that methylation of
the miR-375 upstream CpG island is melanoma stage-speciﬁc.
Minimal CpG island methylation was observed in melanocytes,
keratinocytes, and stage 1 melanoma cell lines, but hypermethyla-
tion was observed in cell lines from more advanced melanoma.
Consistent with this ﬁnding, miR-375 CpG island methylation
was observed in patient tissue samples from primary, regional, dis-
tant, and nodular metastatic melanoma, but not in normal skin and
nevus. miR-375 expression was low in patient samples compared
to melanocytic nevi and normal skin. Ectopic expression of miR-
375 inhibited melanoma cell proliferation, invasion, and wound
healing, and induced changes in cell morphology, strongly suggest-
ing a physiological role for miR-375 in cytoskeletal architecture,
cell motility, and migration. Collectively, our data show that miR-
375 is epigenetically regulated in melanoma, but not in melano-
cytes, keratinocytes, or melanocytic nevi, and plays an important
role in melanoma cell invasion and proliferation. Together, these
data indicate that miR-375 may have an important function in
the development and progression of human melanoma.
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